1 **Title**: Perspectives of Heart Transplant Patients and Providers on Acute Rejection
2 Surveillance: A Mixed-Methods Study
3

4 **Authors:** Hyoungmin Kim,[1] Vincenzo Cusi,[1] Melissa McLenon,[1] Jose Benjamin Cruz
5 Rodriguez,[1] Quan M. Bui,[1] Jennifer Chak,[1] Marcus Anthony Urey,[1] Justin Cole,[1]
6 Rebecca Fielding-Miller,[2,3,4] Paul J. Kim[1]
7
ORCID IDs: Hyoungmin Kim, BA: 0009-0007-4411-5925; Vincenzo Cusi, BS: 0000-
0001-9681-6896; Melissa McLenon, DNP, ACNP: 0009-0005-7470-8233; Jose
Benjamin Cruz Rodriguez, MD, MPH: 0000-0002-2022-6141; Quan M. Bui, MD: 0000-
0001-6070-6978; Jennifer Chak, BS: 0009-0005-5828-1049; Marcus Anthony Urey, MD:
0000-0001-8311-5003; Justin Cole, MSQA: 0009-0003-9382-477X; Rebecca Fielding-
Miller, PhD, MSPH: 0000-0002-5099-0589; Paul J. Kim, MD, MAS: 0000-0002-1755-
6182
15
16 **Affiliations:** 1. UC San Diego Health, La Jolla, CA. 2. Herbert Wertheim School of
17 Public Health and Human Longevity Science, University of California San Diego, San
18 Diego, CA. 3. Center on Gender Equity and Health, School of Medicine, University of
19 California San Diego, San Diego, CA. 4. Division of Infectious Disease and Global
20 Public Health, School of Medicine, University of California San Diego, San Diego, CA

21
22 **Total Word Count**: 3,938
23

Author contributions:
HK: investigation, methodology, writing – original draft, writing – review & editing, data
curation, formal analysis, funding acquisition; VC: investigation, methodology, writing –
original draft, data curation, formal analysis, supervision; MM: investigation,
methodology, writing – review & editing; JBCR: investigation, writing – review & editing;
QMB: investigation, writing – review & editing; JChak: investigation, writing – review &
editing; MAU: investigation, methodology, writing – review & editing; JCole:
investigation, formal analysis, writing – review & editing; RFM: investigation,
methodology, formal analysis, writing – original draft, writing – review & editing,
supervision; PJK: conceptualization, investigation, methodology, writing – original draft,
writing – review & editing, data curation, formal analysis, project administration,
supervision, funding acquisition.

Correspondence

Paul J. Kim, MD, MAS

Division of Cardiovascular Medicine

Department of Medicine

UC San Diego Health

9452 Medical Center Drive, MC 74II

La Jolla, CA 92037

Tel: 858-246-O638

Fax: 858-657-5O28

E-mail: pjk0I7@ucsdhealth.edu

49
50

51 **Abbreviations**:
52
APP, advanced practice provider
COREQ, Consolidated Criteria for Reporting Qualitative Research
dd-cfDNA, donor-derived cell-free DNA
GEP, gene-expression profiling
HTx, Heart transplant
EMB, endomyocardial biopsy
EMR, electronic medical record
NRC Health, National Research Corporation Health
RCT, randomized controlled trial
RN, registered nurse
RT, radiologic technologist
SRQR, Standards for Reporting Qualitative Research
UCSD, University of California, San Diego

Keywords:

Endomyocardial biopsy; heart transplant; clinical practice guidelines; donor-derived cell-

free DNA test; patient perspectives

Abstract

Background:

Endomyocardial biopsies (EMB) remain the reference standard for detection of acute rejection in heart transplant (HTx) patients. Recent studies evaluating novel noninvasive tests have sparked a renewed discussion in the HTx community about revising acute rejection surveillance policies. However, patient and provider perspectives remain underexplored. This single-center study examined both HTx patient and provider perspectives on replacing EMBs earlier with noninvasive blood tests.

Methods:

We performed semi-structured interviews with 28 HTx patients to explore their perspectives on replacement of EMBs with donor-derived cell-free DNA (dd-cfDNA) early post-HTx. We subsequently conducted a survey of 118 HTx patients using self-administered online questionnaires. We also performed semi-structured interviews with 18 HTx providers to explore their perspectives. Thematic analysis was performed on interview and open-ended survey responses using deductive and inductive approaches. Patient quantitative survey responses were analyzed with descriptive statistics.

Results:

Our study identified three key themes: patient anxiety related to EMBs, importance of

patient-provider communication, and strong interpersonal trust in providers by HTx

patients. Although 78.4% of patients experienced EMB-related anxiety, they prioritized

testing accuracy to ensure "the health of their new heart." Consequently, patients

favored the most accurate testing protocol and trusted providers to make this decision

(91.1%). HTx providers raised concerns about the accuracy and safety of noninvasive

surveillance testing for high risk patients.

Conclusion:

HTx patients trusted their providers to determine the most accurate acute rejection

surveillance policy. Additionally, our study provides important patient-centered priorities

to guide the implementation of early noninvasive testing into clinical practice.

INTRODUCTION

While EMBs are the reference standard of detecting acute rejection post-HTx, there is

active research to replace surveillance EMBs earlier with noninvasive testing, due to

potential complications associated with EMBs.[1–3] The IMAGE trial was the first

randomized controlled trial (RCT) that demonstrated the safety of replacing surveillance

EMBs with gene-expression profiling (GEP) blood tests in low risk HTx patients.[4] More

recently, novel noninvasive tests, such as dd-cfDNA testing, have shown promise in

further reduction of surveillance EMBs in the early post-HTx period and also in detecting

antibody-mediated rejection.[3,5,6] As a result, a number of HTx centers have changed

their institutional policies to increasingly utilize noninvasive tests in place of surveillance

EMBs, starting as early as 2 to 4 weeks post-HTx.[1,5,7] However, the perspectives of HTx

patients and providers on proposed changes to acute rejection surveillance policy have

not been fully explored.

This study leveraged a unique opportunity to obtain patients' and providers'

perspectives on EMBs at our institution, where policy changes to replace EMBs with dd-

cfDNA are being considered early post-HTx. We hypothesized that the majority of HTx

patients would strongly advocate for replacing EMBs earlier with noninvasive testing.

These findings will inform the integration of early noninvasive testing into future patient-

centered policy and guideline changes.[8]

MATERIALS & METHODS

Study Design

This was a mixed-methods study conducted at University of California, San Diego

(UCSD) of HTx patients who underwent EMB and the HTx providers who treat these

patients. This study was performed in 2 parts: a qualitative part of semi-structured

interviews of HTx patients and providers and a quantitative part of a larger cohort of

HTx patients using a self-administered online survey. This study was overseen by a

multidisciplinary research team with expertise in HTx (VC, MM, JBCR, QMB, MAU, and

PJK) and qualitative methodology (QMB and RFM). We followed the Consolidated

Criteria for Reporting Qualitative Research (COREQ) and Standards for Reporting

Qualitative Research (SRQR) guidelines to report this study.[9,10]

Participants

Adult HTx patients, who were 18 years of age or older, transplanted from August 2021

to June 2023, and had previously undergone at least one EMB, were recruited

consecutively during scheduled clinic visits for semi-structured interviews (conducted

from June to August 2023). At our institution, surveillance EMBs range from 4-10

months post-HTx, dependent on HTx patient risk (**Appendix A**). We subsequently

invited HTx patients transplanted from August 2019 to July 2023 to take part in an

online survey that also allowed for open-ended responses.[1] We also conducted semi-

structured interviews of HTx providers from January to March 2024. HTx providers

included board-certified HTx cardiologists, advanced practice providers, nurses, or

radiologic technologists who were 21 years of age or older, had been practicing for at

least 3 years, and directly cared for HTx patients.

Data Collection

Interview guides were developed for HTx patients (**Appendix B**) and providers

(**Appendix C**) based on discussions with the core research team (HK, VC, MM, QMB,

MAU, RFM, and PJK) and were iteratively refined. Firstly, a semi-structured interview

guide was developed that explored patients' perspectives on replacing EMBs earlier

with noninvasive blood tests. Subsequently, a semi-structured interview guide was

developed for HTx providers. Consistent with qualitative methodology, the interview

guide was modified during the study as new topics emerged from the interviews.[11,12] We

then used preliminary results from the qualitative analysis of patient responses to

develop a brief self-administered online survey distributed using Qualtrics software

(Qualtrics International Inc., Seattle, Washington, USA; **Appendix D**). The survey was

available to patients in English and Spanish–the two most common languages at

UCSD. The survey was not pilot tested prior to its distribution. The online survey

responses were anonymized to allow for critical feedback from patients and for HIPAA

compliance per UC San Diego Office of IRB Administration policy.

Analysis

Interviews were conducted and recorded by HK, VC, and MM. We utilized a

standardized telephone script prior to interviewing semi-structured interview patients

and providers. Recorded interviews were transcribed using Otter.ai (Otter.ai Inc.,

Mountain View, California, USA) and were verified for accuracy by HK and VC.

Transcripts were not returned to participants for comments or corrections. Transcripts

were coded and thematic analyses were performed by HK, VC, and PJK. A hybrid

thematic process combining inductive and deductive approaches was followed,

grounded in a post-positivist paradigm.[13] Initial codes were developed deductively

based on prior clinical and research experience related to EMBs. The codes reflected

concepts such as "anxiety," "pain," "rejection surveillance," "communication of findings,"

"reduction of frequency of EMBs," and more. However, our analysis remained open to

inductive insights from participant narratives. Interviews continued until code and

meaning saturation were reached, supervised by PJK, QMB, and RFM. Confidentiality

of data was kept by deidentifying patient and provider responses and assigning unique

code numbers. Qualitative data was managed using Microsoft Excel 16.1 (Microsoft

Corporation, Redmond, Washington, USA). Qualitative analysis of patient interviews

was used to guide quantitative analysis of the online survey as is standard in mixed

sequential designs.[14] Quantitative online survey data was exported and analyzed with

descriptive statistics using R (R Core Team, 2025). Fisher's exact test was used to

compare patient satisfaction scores using patient experience surveys from NRC

(National Research Corporation, Lincoln, Nebraska, USA) Health that were $\geq$ 9 from a

scale from 0-10 (0 being not at all satisfied and 10 being extremely satisfied) 6 months

before and after implementation of suggestions by HTx patients and providers to

improve the patient EMB experience. Thematic analysis was also performed for the

open-ended responses from the online survey.

Regulatory Ethics

All invited survey patient participants were eligible to participate in a drawing to win one

of ten $50 gift cards. Ethics approval was granted by the UCSD Office of IRB

Administration (No. 805675). This study adheres to the principles of the Declaration of

Helsinki formulated by the World Medical Association and the US Federal Policy for the

Protection of Human Subjects. All interviewed subjects gave their informed consent

prior to their inclusion in the study.

RESULTS

Respondent characteristics

For the semi-structured patient interviews, 56 participants were invited and 28 (50.0%)

agreed to participate. For the online survey, 286 patient participants were invited and

118 surveys were completed (41.3%). HTx provider interviews included 7 HTx

physicians, 5 registered nurses (RN), 4 advanced practice providers (APP), and 2

radiologic technologists (RT).

Respondent characteristics for interviewed patients are shown in **Table 1**. The number

of sensitized patients (panel of reactive antibodies ≥ 10%) was 14.3%.[3] There were 18

(64.3%) low, 4 (14.3%) moderate, and 6 (21.4%) high risk patients. All EMBs were

performed using fluoroscopy guidance and 86.7% were performed using the right

internal jugular vein as access.[15] The median number of EMB per patient participant at

the time of the study was 8 (IQR, 7 - 10). Most EMBs were performed in an outpatient

setting (76.4%) and performed for surveillance indication (83.5%). The median time

from HTx to semi-structured interviews was 89 days (IQR, 52 - 172 days). Interviews

lasted a median time of 14 minutes (IQR, 12 - 17.5 minutes).

HTx patient perspectives

Semi-structured interviews

Three common themes were identified: (1) patient anxiety related to EMBs, (2)

importance of patient-provider communication, and (3) strong interpersonal patient trust

in providers by HTx patients (**Table 2**).

Patient anxiety related to EMBs

Interviewed patients commonly described anxiety related to EMBs. This anxiety often

started in the waiting room for patients and was exacerbated by delays that were not

communicated to patients. In addition, a few patients described increased pre-

procedural anxiety due to prior negative EMB experiences.

'I [get] anxious a little bit because of that initial time when I was like tremoring on the

table. I'm always afraid it's gonna hurt really bad… it was just like, horrible pain. And

you know, because of that I do get anxious before the procedures.' – Interview Patient

Participant 2

'My apprehension and anxiousness increases when there is a delay… I have to sit there

and never know exactly when I'll be taken… it's just not a good experience.' – Interview

Patient Participant 21

Patients frequently cited that the most distressing and painful part of EMBs was the

lidocaine injection. Suggestions for changes to the EMB experience to reduce anxiety

were also provided by patients (**Table 2**).

'If they take a little longer after the anesthesia kicks in, [the biopsy experience] will be

100% better. Right now [it] is 95%.' – Survey Participant 24

'I just want to be able to look around and see the room and not feel so confined

underneath the whole cover itself.' – Interview Patient Participant 1

'[I told the fellow who did my biopsy] for the future [to] come around and introduce

yourself because that would have been nice to know.' – Interview Patient Participant 27

While a few HTx patients may experience negative EMB experiences, many interviewed

patients considered surveillance EMBs a necessity despite the potential pain associated

with EMBs.

'I think it's vitally important that if there is something going on that they get ahead of it

early on, [catch it], [and] get rid of it.' – Interview Patient Participant 1

'Even if everything was really painful, it's totally worth it. You're not gonna hear

complaints from me.' – Interview Patient Participant 12

A minority (32.1%) of interviewed patients expressed their desire for alternatives to

frequent surveillance EMBs due to their anxiety, previous poor EMB experience, and

perceived risks. Additionally, some of the perceived EMB risks were attributed to

information from sources other than the patients' providers.

'I think [the EMB frequency] is a little bit too much. Now, it's like every two weeks but it

will [get] better. It will be like one in a month and then one in a year. [Right] now it's just

the beginning, so it's hard.' – Interview Patient Participant 15

'A yearly biopsy where there are no signs of rejection or cause for concern seems

unnecessary considering the risk [of EMBs].' – Survey Participant 15

'[I would prefer less biopsies] because my wife said that [EMBs] are dangerous.' –

Interview Patient Participant 6

Importance of patient-provider communication

Compassionate and consistent patient-provider communication was considered an

important component by patients before, during, and after EMBs (**Figure 1** and **Table**

2). Good patient-provider communication not only reduced patient anxiety but also

allowed patients to feel included in their care.

'You have a heart transplant and every doctor who comes in knows your whole life

story… We went through everything and asked me questions, they already knew where

I grew up, where I'm from, and that I have kids and stuff like that… They knew [about

me] and that helped a lot.' – Interview Patient Participant 14

'It helps to calm the patient or make them feel more comfortable if they're not left laying

on the table by themselves staring at the wall while the staff is on the other side of the

room talking.' – Survey Participant 109

'[The] last time I went, I got to see everything on the screen. And [the doctor] was

explaining to me what those things were [on] the sternum.. I [saw] the little wings and

[the doctor said] 'oh, you got extra hardware in there'... I learned about that.' – Interview

Patient Participant 6

Patients also stated their desire for the return of their biopsy results in a timely manner

and in a language understandable to them.

'But if you don't hear from the team, it's just assumed that the biopsy was either a zero

or a one… I would prefer to see that as a last result in my medical records, so I don't

have to wonder.' – Interview Patient Participant 21

'I'd like to look at pictures… [the EMB results] doesn't really tell me much [as a layman].'

– Interview Patient Participant 2

Strong interpersonal trust in providers by HTx patients

HTx patients commonly described their strong interpersonal trust with their providers. A

subtheme identified was that patients felt the final decision related to acute rejection

surveillance should ultimately come from their HTx team. Patients who had negative

experiences with EMBs also continued to trust their providers' recommendations.

'I've never had a heart transplant before this one. I don't have a professional opinion on

that. I just know what the doctors are saying [and] this is what we need to do.' –

Interview Patient Participant 1

'I've got scar tissue on my neck now… you know, it hurts… but [the doctors] know what

they're doing… so I comply.' – Interview Patient Participant 2

'I think [determining biopsy frequency] should really be up to the cardiologists… The

end goal surpasses any kind of inconvenience.' – Interview Patient Participant 12

Interpersonal trust was established at the beginning of the relationship with HTx

providers and patients. This trust was strengthened further through consistent and

compassionate communication, building a sense of camaraderie with the HTx team.

'I put my hands up to the doctor six years ago now. I said I tried doing it myself [and] it

didn't work… the team has been awesome.' – Interview Patient Participant 17

'One thing you guys did [that] was really good was introduce the entire cardiology team

on the front end. I [had] nice conversations with everybody. It's kind of like a

camaraderie.' – Interview Patient Participant 12

'The doctors explained it so many times what they're doing and why they're doing it

[that] I trust what they're gonna do.' – Interview Patient Participant 22

Gratitude and a feeling of indebtedness were also frequently associated with strong

interpersonal trust in the HTx team.

'I got a new lease on life. The heart they pulled out of me was down to 8%. So for me, I

have two birthdays… I have to do whatever they want… Just trying to comply to the

best of my ability so that I can be well.' – Interview Patient Participant 2

'If I had to do it over again. I would do exactly what you guys said because the way you

guys took care of me is undescribable [sic].' – Interview Patient Participant 25

Ultimately, patients wanted the assessment of their new heart's condition to be

accurate, regardless of the surveillance strategy used. Patients would consider

alternatives if their HTx team considered them to be as accurate as the current acute

rejection surveillance policy.

'[Changes to patients' EMB policy] should really be up to the cardiologists who live with

their decisions… if they do see a significant amount of people losing their lives, what is

that worth? Even if you lose one I [think decreasing EMBs] is not worth it.' – Interview

Patient Participant 12

'You guys know what you're doing. So if you guys think you can cut the number of times

that you can do the biopsy with success, I would say that's great. But, if there's a

problem [with doing that, then] keep going the way you're going.' – Interview Patient

Participant 25

'If it was determined that the outcomes are the same, that would be great... If [EMBs]

were less frequent and have the same outcomes... I can't imagine anybody would be

against that.' – Interview Patient Participant 23

Quantitative (patient online survey questionnaire)

Surveyed patients recalled their average pain associated with EMBs low (2.5 out of 10;

Table 3). In addition, anxiety associated with EMBs decreased with subsequent EMBs

in the majority (78.4%) of survey participants.

Most patients indicated that EMBs are an important part of their post-HTx care (93.0%)

and would support a change in EMB frequency based on their HTx team's

recommendations (91.1%). Additionally, if noninvasive testing is as accurate as

surveillance EMBs, 77.7% of surveyed patients would prefer noninvasive testing over

surveillance EMBs. The patients that continued to prefer surveillance EMBs over

noninvasive testing most often cited their gratitude in their HTx team in their open-

ended responses. These results supported our qualitative findings.

'As a whole, you all do a great job of making me feel comfortable through the

procedure. Thank you all very much.' – Survey Participant 45

'I'm always very appreciative of the high level of care the Docs and staff in the Cath lab

give me. After about 20 - 25 biopsies many of these people have treated me multiple

times. Thanks to them all.' – Survey Participant 63

405 HTx Provider Perspectives

The majority (87.5%) of HTx physicians perceived positive patient experience with

EMBs. This perception was reduced in HTx non-physician providers (APPs, RNs, and

RTs) at 63.6%. However, both HTx physician and non-physician providers considered

EMBs as a necessary part of post-HTx care.

'But most patients have no issues with biopsy... patients go home usually [in] about 20

minutes… they'll just be surprised how easy it was.' – HTx Physician 2

'I mean, it's not something that I think people want to do, but they know it's necessary

and part of the maintenance and care of their heart.' – HTx Non-Physician Provider 8

(APP)

'Patients have called it pretty uncomfortable in the past but I also think that they find a

sense of security with it… it's like confirmation that, you know, their heart is okay.' – HTx

Non-Physician Provider 9 (HTx RN coordinator)

While the majority of HTx providers (83.3%) supported a reduction in the frequency of

surveillance EMBs, there was also concern of the safety of replacing surveillance EMBs

with noninvasive testing, particularly in high risk patients.

"We still need to see how this protocol rolls out with our higher risk patients… I think we

figure that out first, and then maybe it would be a good future goal." – HTx Non-

Physician Provider 11 (HTx RN coordinator)

'[EMB] gives me a sense of comfort in those first few months where [the patients] are

really high risk… I feel like we could cut [the EMB frequency] some, but I couldn't

personally see getting rid of them completely.' – HTx Non-Physician Provider 9 (HTx RN

coordinator)

'Early surveillance [noninvasive testing is] not as reliable. So I think very early on no.' –

HTx Physician 7

HTx providers (88.9%) also supported many of the suggestions by patients to improve

the EMB experience (**Figure 1**). Although HTx physicians agreed on the importance of

patient-provider communication, 28.6% expressed reluctance to deliver EMB results

electronically, citing risks of heightened patient confusion and anxiety.

'I just think involving the patients. I think that's why they want to know what the results

are even if they don't understand them. They just want to feel involved… and not just

have everybody talking about them like they're a child… they're adults and they want to

feel empowered.' – HTx Physician 4

'I try to check in even in clinics to say, "how are your biopsies going?"... it's another

procedure to us, right, but it's such a big deal in their life that we kind of miss some

opportunities to communicate better to them.' – HTx Non-Physician Provider 9 (HTx RN

coordinator)

'It's really a nuanced kind of response looking at the histology… [it might cause] more

questions [for] patients.' – HTx Physician 7

After making changes suggested by patients and providers (**Figure 1**), we observed a

trend in improved patient satisfaction related to EMBs (odds ratio = 1.75; 95%

confidence interval, 0.76-4.27; p = 0.155).

DISCUSSION

To our knowledge, this is the first study evaluating HTx patient and provider

perspectives on EMBs and proposed changes to an institutional acute rejection

surveillance policy. Our findings identified three key themes: 1) patient anxiety related to

EMBs, 2) importance of patient-provider communication, and 3) strong interpersonal

trust in providers by HTx patients. Ultimately, HTx patients prioritized the most accurate

testing protocol, whether EMB or noninvasive, to safeguard their new heart's health.

Both thematic analysis and quantitative data confirmed that HTx patients trust providers

to select the most effective acute rejection surveillance strategy. However, HTx

providers expressed ongoing concerns about the safety and accuracy of early

noninvasive testing, particularly in high risk patients.

Previously, others assessed the EMB experience using patient surveys in clinical

studies focused primarily on the safety of noninvasive testing.[1,4] In contrast, we used a

mixed-methods approach to examine HTx patient and provider perspectives before any

institutional policy changes, as recommended by international guideline standards.[16,17]

Our study revealed that HTx patients offered nuanced priorities for post-HTx

surveillance testing, not described before in the literature. In our semi-structured

interviews, HTx patients prioritized accurate testing to ensure their heart health over

their temporary anxiety from EMBs, which diminished with familiarity. Patients trusted

providers to recommend the most accurate surveillance test. Similarly, both HTx

physician and non-physician providers emphasized testing accuracy over patient

anxiety. These findings align with other medical fields where patients value the clear

benefits of accurate, albeit invasive, testing.[18]

HTx patients frequently expressed gratitude for their post-HTx care when reflecting on

their EMB experience. Although the recalled pain of EMBs diminished with experience,

HTx patients' gratitude and sense of indebtedness persisted over time. This gratitude

was closely tied to strong interpersonal trust in their providers, leading patients to rely

on their providers' judgment when considering changes to institutional policies for acute

rejection surveillance strategies. Likewise, patient trust in providers has been

recognized as a critical factor in decision-making in other solid organ transplant

fields.[19,20]

Our study findings demonstrated that providers sought to decrease the frequency of

surveillance EMBs, reflecting the perspectives of the HTx community.[1,21] However, HTx

providers expressed concerns about the safety of early noninvasive surveillance testing

for high risk patients. The three RCTs comparing noninvasive testing to surveillance

EMBs have only included low risk HTx patients.[2,4,22] Thus, to convince providers that

noninvasive testing can supplant the current standard of surveillance EMBs early post-

HTx, more data from RCTs are needed that include high risk patients. Currently, one

multicenter RCT (ClinicalTrials.gov NCT06414603) is underway to address this critical

knowledge gap.

Even with evolving policies and guidelines on surveillance testing, EMBs will likely stay

essential in post-HTx care because of for-cause testing.[15,21] In our study, both HTx

patients and providers offered actionable recommendations for integration into any HTx

program (**Figure 1**).

Several limitations should be considered when interpreting the results of this study.

First, this was a single center study and may not necessarily represent HTx patient and

provider perspectives of other centers. Second, our study focused on proposed policy

changes for acute rejection surveillance and thus, our key themes require validation for

other aspects of post-HTx care. Third, we acknowledge that most patients did not have

complications with their EMBs, which may have impacted their opinions on EMBs.

However, previously we found EMB complications to be relatively rare.[15] In addition, the

few patients that did have EMB complications still demonstrated strong interpersonal

trust in their providers in our study. Fourth, as our institution has not yet changed our

policy for acute rejection surveillance, we were not able to compare results with

perspectives after any changes to our institutional policy. However, 9 (32.1%) low,

moderate, and high risk patients experienced both EMB and noninvasive surveillance

strategies and we found similar results in our thematic analysis. Fifth, volunteer bias is

also a potential limitation for our study as patients with positive experiences may have

been more inclined to participate. However, we attempted to mitigate this limitation

through the use of anonymous online survey responses, allowing for more critical

feedback from patients. We found no significant difference in patient age ($p = 0.723$),

sex ($p = 0.629$), and race/ethnicity ($p = 0.570$) between the interviewed and non

interviewed patients.

CONCLUSION

We found that the majority of HTx patients prioritized the most accurate acute rejection

surveillance strategy and trusted their providers to select it. Our findings offer valuable

patient and provider perspectives to inform future clinical practice guidelines.

ACKNOWLEDGEMENTS

The investigators would like to thank all the patients and providers who participated in

this study. The authors also acknowledge Michelle H Kim, PharmD, for her review and

editing of the final manuscript, and Shelley Orr, RN, Ellen Ashman, NP, Amanda Topik,

NP, Amanda Giovanetti, RN, Carmela Zwanziger, RN, Kathleen Cawelti, BSN, RN,

Ashley Cardenas, MAS, and Deepa Kurup, RN, MSN, MBA in collecting patient data

and distributing the patient satisfaction questionnaires.

FUNDING INFORMATION

The project was supported by the Williams College Class of 1966 Career Center for Alumni Sponsored Internship Programs (HK) and the National Institutes of Health Grants **UM1TR005449** and **KL2TR005441** (PJK). The content is solely the responsibility of the authors and does not necessarily represent the official views of Williams College nor the NIH.

CONFLICT OF INTEREST STATEMENT

PJK reports having received payments from One Lambda for travel compensation for a

conference presentation and working at an institution that received research payments

from CareDx and Natera. Neither One Lambda, CareDx, or Natera were involved in the

conceptualization of the study, data collection and analysis, manuscript preparation, and

editing of the final manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are openly available in Mendeley Data (doi:10.17632/hr6kvn9y4h.1).

REFERENCES

1. Amadio JM, Rodenas-Alesina E, Superina S, et al. Sparing the Prod: Providing an Alternative to Endomyocardial Biopsies With Noninvasive Surveillance After Heart Transplantation During COVID-19. *CJC Open*. 2022;4(5):479-487. doi:10.1016/j.cjco.2022.02.002

2. Anthony C, Imran M, Pouliopoulos J, et al. Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation. *Circulation*. 2022;145(25):1811-1824. doi:10.1161/CIRCULATIONAHA.121.057006

3. Khush K, Hall S, Kao A, et al. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. *J Heart Lung Transplant*. 2024;43(9):1409-1421. doi:10.1016/j.healun.2024.05.003

4. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. *N Engl J Med*. 2010;362(20):1890-1900. doi:10.1056/NEJMoa0912965

5. Saeyeldin A, McKean S, Van Zyl J, Darst V, Hall S. A modern heart transplant rejection surveillance protocol utilizing cell-free DNA: A single-center experience. *JHLT Open*. 2024;4(100076):100076. doi:10.1016/j.jhlto.2024.100076

6. Shah P, Agbor-Enoh S, Bagchi P, et al. Circulating microRNAs in cellular and antibody-mediated heart transplant rejection. *J Heart Lung Transplant*. 2022;41(10):1401-1413. doi:10.1016/j.healun.2022.06.019

7. Henricksen EJ, Moayedi Y, Purewal S, et al. Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation. *Clin Transplant*. 2023;37(3):e14699. doi:10.1111/ctr.14699

8. Armstrong MJ, Rueda JD, Gronseth GS, Mullins CD. Framework for enhancing clinical practice guidelines through continuous patient engagement. *Health Expect*. 2017;20(1):3-10. doi:10.1111/hex.12467

9. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349-357. doi:10.1093/intqhc/mzm042

10. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med*. 2014;89(9):1245-1251. doi:10.1097/ACM.0000000000000388

11. Green J, Thorogood N. *Qualitative Methods for Health Research*. 4th ed. SAGE Publications; 2018:1-440. Accessed October 12, 2025. https://www.torrossa.com/resources/an/5018381

12.   Miles MB, Huberman AM. Qualitative data analysis: a sourcebook of new
methods.   Ca.   Accessed   October   12,   2025.
https://www.sidalc.net/search/Record/dig-unesdoc-ark:-48223-
pf0000168413/Description

13.   Bui QM, Thompson JS, Berninger T, et al. Patient perspectives on genetic
testing in transthyretin amyloid cardiomyopathy: Framing the conversation to
improve implementation. *Journal of Cardiac Failure - Intersections*. Published
online August 2025. doi:10.1016/j.yjcafi.2025.05.002

14.   Leech NL, Onwuegbuzie AJ. A typology of mixed methods research
designs. *Qual Quant*. 2009;43(2):265-275. doi:10.1007/s11135-007-9105-3

15.   Cusi V, Vaida F, Wettersten N, et al. Incidence of acute rejection
compared with endomyocardial biopsy complications for heart transplant patients in
the   contemporary   era.   *Transplantation*.   2024;108(5):1220-1227.
doi:10.1097/TP.0000000000004882

16.   Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing
guideline development, reporting and evaluation in health care. *CMAJ*.
2010;182(18):E839-E842. doi:10.1503/cmaj.090449

17.   Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research
evidence in guideline development: 10. Integrating values and consumer
involvement. *Health Res Policy Syst*. 2006;4(1):22. doi:10.1186/1478-4505-4-22

18.   Lohrisch C, Francl M, Sun S, Villa D, Gelmon KA. Willingness of breast
cancer patients to undergo biopsy and breast cancer clinicians' practices around
seeking biopsy at the time of breast cancer relapse. *Breast Cancer Res Treat*.
2018;168(1):221-228. doi:10.1007/s10549-017-4586-9

19.   Khalili M, Cardinal H, Ballesteros F, Fortin MC. Kidney transplant
candidates' and recipients' perspectives on the decision-making process to accept
or refuse a deceased donor kidney offer: Trust and graft survival matter. *Clin
Transplant*. 2022;36(5):e14604. doi:10.1111/ctr.14604

20.   Toal M, Raynor M, McKeaveney C, et al. "Was my kidney biopsy worth
it?"-A qualitative phenomenological study of patient experiences and perceived
barriers   to   kidney   biopsy.   *PLoS   One*.   2024;19(9):e0310358.
doi:10.1371/journal.pone.0310358

21.   Holzhauser L, DeFilippis EM, Nikolova A, et al. The End of
Endomyocardial Biopsy?: A Practical Guide for Noninvasive Heart Transplant
Rejection   Surveillance.   *JACC   Heart   Fail*.   2023;11(3):263-276.
doi:10.1016/j.jchf.2022.11.002

22.   Kobashigawa J, Patel J, Azarbal B, et al. Randomized pilot trial of gene
expression profiling versus heart biopsy in the first year after heart transplant: early

invasive monitoring attenuation through gene expression trial. *Circ Heart Fail*.
2015;8(3):557-564. doi:10.1161/CIRCHEARTFAILURE.114.001658

23.   Khush KK, Patel J, Pinney S, et al. Noninvasive detection of graft injury
after heart transplant using donor-derived cell-free DNA: A prospective multicenter
study. *Am J Transplant*. 2019;19(10):2889-2899. doi:10.1111/ajt.15339

24.   Kim PJ, Alam AH, Teuteberg JJ, et al. Donor-derived cell-free DNA in
antibody-mediated rejection: An analysis of the Surveillance HeartCare Outcomes
Registry. *JACC Heart Fail*. 2025;(102716):102716. doi:10.1016/j.jchf.2025.102716

684 **Table 1**. Patient Characteristics for Semi-Structured Interviews (n = 28 patient
685 participants).

Table 1.	
Recipient characteristics	
Age, y, mean (SD)	60.1 (10.4)
Male, N (%)	22 (78.6)
Race	
Asian, N (%)	1 (3.6)
Black, N (%)	2 (7.1)
Other Race, N (%)	6 (21.4)
Pacific Islander, N (%)	1 (3.6)
White, N (%)	18 (64.3)
Ethnicity	
Hispanic or Latino, N (%)	3 (10.7)
Recipient BMI, mean (SD)	27.2 (6.6)
Indication for Transplant	
NICM, N (%)	16 (57.1)
ICM, N (%)	11 (39.3)
Re-HTx, N (%)	1 (3.6)
Allosensitization pre-HTx (PRA $\geq$ 10%), N (%)	4 (14.3)
Patient Risk Status	
Low Risk (%)	18 (64.3)
Moderate Risk (%)	4 (14.3)
High Risk (%)	6 (21.4)

Durable MCS at time of HTx, N (%)	6 (21.4)
HTx characteristics	
Multiorgan transplant, N (%)	4 (14.3)
Induction therapy, N (%)	9 (32.1)
De novo DSA, N (%)	5 (17.9)

686   Abbreviations: BMI, body mass index; DSA, donor-specific antibody; HTx, heart
687   transplantation; ICM, ischemic cardiomyopathy; MCS, mechanical circulatory support;
688   NICM, nonischemic cardiomyopathy; PRA, panel reactive antibodies

719   **Table 2.** Major Themes, Representative Quotations, and Proposed Approaches to
720   Improve the EMB Patient Experience

Major Themes	Illustrative Quotations	Proposed Approaches
Patient Anxiety	*"If they take a little longer after the anesthesia kicks in, [the biopsy experience] will be 100% better. Right now [it] is 95%." (Survey Participant 24)*	● Allow time for lidocaine to settle. ● Communicate waiting room delays promptly. ● Ask for patient's preferences in music during the EMB
Patient-Provider Communication	*"Every time they ask me how are you feeling, how are you doing. They ask you about 10 times during the biopsy. That's what makes me feel good." (Patient Participant 7)*	● Introduce patients to the HTx team prior to draping. ● Check-in with the patient regularly. ● Provide a simple explanation of EMB results in a timely fashion.
Trust in Providers	*"The doctors explained it so many times what they're doing and why they're doing it [that] I trust what they're gonna do." (Patient Participant 22)*	● Acknowledge patient anxiety related to EMBs. ● Address communication barriers throughout the EMB process. ● Include patient participation in their own care before, during, and after EMBs.

737
738

739 **Table 3**. Patient Online Survey Results (n = 118 patient participants).

Survey question	Survey response Median (Interquartile range)	Percent of responses that somewhat or strongly agree ($\geq$4)
How much pain do you experience during a biopsy? From 0 (no pain) to 10 (worst pain).		
During an average biopsy?	2.5 (1.0-4.0)	-
During your most painful biopsy?	4.0 (2.0-7.0)	-
How much do you agree with the following statements? From 1 (strongly disagree) to 5 (strongly agree).		
Endomyocardial biopsy is an important part of my post-transplant care.	5.0 (5.0-5.0)	93.0%
I initially felt anxious about biopsies, but this improved with experience.	5.0 (4.0-5.0)	78.4%
The physicians/staff do a good job communicating with and comforting me during the biopsy.	5.0 (5.0-5.0)	94.7%
My biopsies are typically on time.	4.0 (3.0-5.0)	71.7%
My biopsy results are communicated well to me.	5.0 (4.0-5.0)	90.2%
Following a biopsy, I feel like I can do my normal activities.	5.0 (4.0-5.0)	86.7%

If there was a non-invasive alternative that was as accurate as a biopsy, I would prefer it.	5.0 (4.0-5.0)	77.7%
I would support a change in biopsy frequency based on my team's recommendations.	5.0 (5.0-5.0)	91.1%
The procedure is more comfortable with certain providers compared to others.	4.0 (3.0-5.0)	68.5%
Which access site did you prefer for your biopsies (for patients who had experience with both arm and neck access; n = 37)?	-	Neck (43.2%) Arm (24.3%) No Preference (32.4%)

Pre-EMB	During EMB	Post-EMB
▪ Recognition that anxiety, good communication, and trust-building start pre-EMB. ▪ Communicate anticipated delays in procedure start time. ▪ Introduce the patient to HTx team members.	▪ Involve patients during the EMB (e.g., asking for their music preferences, explaining the steps during the procedure, and sharing available information about the patient's heart). ▪ Have a HTx team member delegated to consistently ask how the patient is doing. ▪ If there are changes in the operator, announce the change in roles to the patient.	▪ Provide return of results, including negative results, in a timely fashion. ▪ Have a system to consistently ask patients for suggestions after EMBs. ▪ Provide feedback to HTx team members regularly.

759   **Figure 1.** Anxiety, Communication, and Trust-building throughout the patient journey for

760   EMBs. Patients and providers provided practical suggestions to reduce patient anxiety,

761   improve patient-provider communication, and strengthen patient trust throughout the

762   three stages of a patient's EMB experience (before, during, and after).

779